Navigation Links
Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
Date:10/10/2011

nds towards benefit for lung function measures. The Forced Expiratory Volume in one second (FEV1) decreased in the placebo group as compared to baseline at 26 weeks (change: -5.6%; p=0.0582) with no such deterioration being observed in the AIMSPRO treated group. Similarly, the Forced Vital Capacity (FVC) was observed to decrease in the placebo group as compared to baseline at 26 weeks (change: -5.6%, p=0.1038), but not in the AIMSPRO treated group, where the FVC showed an increase (change:+1.8%, p=0.3225).

"Although requiring further confirmatory studies, these results are quite exciting, especially when compared to what has been seen in other pilot trials in scleroderma as there is a clear unmet medical need for patients suffering with this life-threatening disease" said Professor Christopher Denton, Professor of Experimental Rheumatology at the Royal Free Hospital in London, United Kingdom, the principal investigator for the trial. "The important value of the safety data from such a well-conducted trial in such a serious disease is clear, apart from the signals of therapeutic benefit."

Daval's Clinical and Scientific Director, Professor Syed Haq commented, "This study, conducted at one of the world's leading scleroderma centres, was an important first step towards understanding whether AIMSPRO could significantly help patients with diffuse scleroderma and potential overlapping connective tissue disorders, for which there is no cure, by arresting the disease even in its latter stages. AIMSPRO has been shown to be well-tolerated and safe and with the several positive therapeutic signals demonstrated, some of which were significant, it certainly warrants further investigation on a larger scale to determine the full efficacy of AIMSPRO in Late Stage Established Diffuse Cutaneous Systemic Sclerosis."

At the completion of the 26 week period of the study, AIMSPRO was offered to the patients on a compassionate
'/>"/>

SOURCE Daval International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
(Date:10/17/2014)... Oct. 17, 2014 A victim of medical negligence ... doctor with a history of alcohol abuse, a physician ... on Prop 46 today, highlighting how Prop 46 will identify ... testing. The ad pictures a doctor drinking ... To ER."  Proposition 46 will enact the first law in ...
(Date:10/17/2014)... 2014   InnFocus, Inc ., reported on results of ... for up to 3 years with the InnFocus ... Chicago . The Summit ... meeting of the American Academy of Ophthalmology . The ... glaucoma patients in 6 countries by early 2015. ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
... LITTLE FALLS, N.J. , May 26 CANTEL ... Andrew A. Krakauer , President & CEO, will be presenting at the ... 9:00 AM ET on Wednesday, June 9, 2010 ... a Q & A session immediately following the presentation. In addition, Mr. ...
... BOSTON , May 26 Solos Endoscopy, Inc. ... $104,774 in revenues for the first quarter ended ... the first quarter 2009, which represents a 10 percent increase. As ... in total assets. The Company has posted its financial results for ...
Cached Medicine Technology:Cantel Medical Corp. to Present at the Jefferies 2010 Global Life Sciences Conference 2Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009 2
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Aliso Viejo, California (PRWEB) October 20, 2014 ... have announced the release of the Citrus theme for ... words I would use to describe the Citrus theme” Says ... been so easy to look so professional.” , Citrus comes ... . Included with the template are: four transitions for added ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... learned that you were at high risk of cancer because ... your children? A recent study at Fox Chase Cancer Center ... the next level and studied the parent perceptions of the ... be presented at the 2009 Annual Meeting of the American ...
... Chase Cancer Center uncovered a genetic pattern that may ... to the targeted therapy imatinib mesylate (Gleevec). Moreover, ... in order to make these tumors respond more readily ... in the laboratory of Andrew K. Godwin, PhD, at ...
... new pharmaceutical products in the pipeline combined with new ... the rare disease community, a senior Food and Drug ... by the National Organization for Rare Disorders (NORD).The blockbuster ... director of the Center for Drug Evaluation and Research ...
... 14 Hanger Orthopedic Group Inc. (NYSE: ... in the S&P SmallCap 600 after the close of trading ... acquired by privately held TriNet Group, Inc. in a transaction ... and post any relevant updates on its website: ...
... MedServe, Inc., a private company, today announced that it ... Stericycle, Inc. (Nasdaq: SRCL ) for $185 ... Avista Capital Partners, Chrysalis Ventures and Murphree Venture Partners ... collection, transportation, treatment and disposal of medical waste, hazardous ...
... ImQuest Bio and Arisyn jointly presented important ... inhibitor of hepatitis C virus (HCV) replication, at the 13th ... presentation highlighted the ability of PG301029 to potently suppress the ... potential mechanism of antiviral action through the selection of a ...
Cached Medicine News:Health News:Should parents share the results of BRCA1/2 genetic testing with their children? 2Health News:Gene signature may predict patient response to therapy for gastrointestinal stromal tumors 2Health News:NORD Sponsors Rare Disease Summit 2Health News:Standard & Poor's Announces Changes to U.S. Index 2Health News:MedServe to be Acquired by Stericycle for $185 Million 2Health News:MedServe to be Acquired by Stericycle for $185 Million 3Health News:ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference 2
... of Surgical Microscope Accessories includes digital camera ... cables, and fiberoptic retrofits. TTI Medical's patented ... 5,264,928) is the only adaptor that will ... the same adaptor body. It is fully ...
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
... WAVEFRONT ANALYZER provides a complete ... the entire eye. Real-time measurements ... aberrations in many different forms ... higher order aberrations, Zernike polynomials, ...
Medicine Products: